First Postpartum Depression Drug Fast Tracked and Licensed by FDA
On Aug. 4, 2023, the U.S. Food and Drug Administration (FDA) fast tracked licensure of the oral prescription medication Zurzuvae (zuranolone), manufactured by Sage Therapeutics, Inc. as a treatment for postpartum depression. Postpartum affects roughly one in seven women and typically begins after childbirth but, for some women, it can begin during later stages of […]
COVID-19 Hospitalized Patients and Underlying Chronic Disease
Story Highlights Recent research shows that most hospitalized COVID-19 patients had one or more chronic poor health conditions, such as obesity, hypertension and heart and lung disease. Chronic diseases are the leading cause of death and disability in the United States, making the U.S. population susceptible to more severe COVID-19 infections. Good nutrition helps reduce […]
